Authors

Latest:

Sheri Holmen on Understanding Drivers of Melanoma Metastasis

Sheri Holmen, PhD, investigator, Associate Professor in the Department of Surgery, Adjunct Professor in the Department of Oncological Sciences, Huntsman Cancer Institute, the University of Utah School of Medicine, discusses understanding drivers for melanoma metastasis.

Sherif S. Farag, MD, Indiana University Health

Sherrif F. Ibrahim, MD, PhD

Latest:

Update on Vismodegib's Place in the Treatment of Advanced BCC

Basal cell carcinoma (BCC) is the most common human malignancy and by far the most prevalent form of skin cancer, accounting for more than 80% of all cases.

Shikha Jain, MD

Latest:

Dr. Jain on the Push Toward Personalized Treatment Approaches in CRC With Liver Metastases

Shikha Jain, MD, FACP, discusses the push toward personalized treatment approaches in colorectal cancer with liver metastases.

Shilpa Gupta, MD, Cleveland Clinic

Latest:

Dr Gupta on Avelumab Maintenance in Urothelial Carcinoma With/Without Diabetes Mellitus

Shilpa Gupta, MD, discusses data from a subgroup analysis of the phase 3 JAVELIN Bladder 100 and future questions surrounding the use of avelumab maintenance in this setting.

Shin Yin Lee, MD

Latest:

Geriatric Oncology: Learning the Balancing Act of Treating the Older Cancer Patient

Whether it be to identify a seemingly frail older patient with metastatic colon cancer who would tolerate and benefit from standard treatment, or to prevent a frail older lung cancer patient from experiencing severe side effects due to adjuvant chemotherapy, oncologists are having to make difficult decisions with increasing frequency.

Shirish Gadgeel, MD

Latest:

Leveraging ctDNA Platforms in High-Risk Patients: Current Applications and Future Potential

Panelists discuss how they currently utilize emerging ctDNA platforms for high-risk patients and explore whether these advancements will soon become standard practice in clinical decision-making.

Shirish Gadgeel, MD, Wayne State University School of Medicine

Shirish M. Gadgeel, MD, MBBS

Latest:

Dr. Gadgeel on the Utility of Liquid Biopsies in Lung Cancer

Shirish M. Gadgeel, MD, MBBS, Mary Lou Kennedy Research Professor in Thoracic Oncology, professor, Department of Internal Medicine, Division of Hematology/Oncology, co-leader, Thoracic Oncology Research Program, and associate director, Networking and Affiliated Centers, University of Michigan Medicine, discusses the utility of liquid biopsies in lung cancer.

Shirish M. Gadgeel, MD, MBBS Rogel Cancer Center

Shirish M. Gadgeel, MD, University of Michigan

Shirley Michelle Shiller, DO

Latest:

Evolution in the Field of HR+ Breast Cancer Management

Closing out their discussion on HR+ breast cancer management, expert panelists share their excitement for the evolving treatment paradigm.

Shivani Parmar, MPH

Latest:

5 Questions... with Cliff Chirls, President and COO of iMedExchange

Clifford Chirls discusses the features of the new social networking site iMedExchange and explains how it diff ers from other social networking resources for physicians.

Shiven B. Patel, MD, MBA, FACP

Latest:

Dr. Patel on Treatment Considerations in Advanced Squamous NSCLC

Shiven B. Patel, MD, MBA, FACP, discusses treatment considerations in patients with advanced squamous non–small cell lung cancer.

Shlomo Koyfman, MD

Latest:

Dr. Koyfman on Reirradiation Options for Head and Neck Cancer

Shlomo Koyfman, MD, associate staff, radiation oncology, Cleveland Clinic, discusses reirradiation options for patients with head and neck cancer.

Shoba A. Navai, MD

Latest:

Dr. Navai on Treatment Options in Relapsed/Refractory Sarcoma

Shoba A. Navai, MD, an assistant professor, Department of Pediatrics, Section of Pediatric Hematology and Oncology, at Baylor College of Medicine, Texas Children’s Hospital, discusses treatment options for patients with relapsed/refractory sarcoma.

Shota Fukuoka, MD

Latest:

Dr. Fukuoka on Dosage for Regorafenib/Nivolumab Combo in Gastric Cancer and CRC

Shota Fukuoka, MD, physician, National Cancer Center in Japan, discusses finding the recommended dosage of regorafenib plus nivolumab in patients with advanced gastric cancer or colorectal cancer.

Shreyaskumar Patel, MD, The University of Texas MD Anderson Cancer Center

Shreyaskumar R. Patel, MD, MD Anderson Cancer Center

Latest:

Supporting Community Practice Through Collaboration

Panelists discuss how communication between community oncologists and academic centers is essential for advancing gastrointestinal stromal tumor (GIST) treatment through clinical trial participation, molecular analysis, and the promising future of personalized therapy based on individual tumor mutation profiles.

Shreyaskumar R. Patel, MD, University of Texas MD Anderson Cancer Center